Abstract: An acrylic fiber for artificial hair may include an acrylic copolymer. The acrylic fiber has a fiber cross section including 2 to 4 T-shaped protrusions that extend radially from a central portion. Each of the T-shaped protrusions has an arc-shaped upper side that bulges in a direction away from the central portion. A circumradius of the fiber cross section is 40.0 to 60.0 ?m. A distance between adjacent end portions of the corresponding upper sides of the adjacent T-shaped protrusions is 3.0 to 60.0 ?m. An axial width is 10.0 ?m or more. Torsional rigidity of the acrylic fiber is 0.30 to 2.0 mg·cm2. The acrylic fiber for artificial hair has high volume, good texture, and good twist processability, and a hair ornament may include the acrylic fiber for artificial hair.

Abstract: An acrylic fiber for artificial hair may include an acrylic copolymer. The acrylic fiber has a fiber cross section including 2 to 4 T-shaped protrusions that extend radially from a central portion. Each of the T-shaped protrusions has an arc-shaped upper side that bulges in a direction away from the central portion. A circumradius of the fiber cross section is 40.0 to 60.0 ?m. A distance between adjacent end portions of the corresponding upper sides of the adjacent T-shaped protrusions is 3.0 to 60.0 ?m. An axial width is 10.0 ?m or more. Torsional rigidity of the acrylic fiber is 0.30 to 2.0 mg·cm2. The acrylic fiber for artificial hair has high volume, good texture, and good twist processability, and a hair ornament may include the acrylic fiber for artificial hair.

Abstract: The present invention relates to the use of cytoxicity based on the effector function of anti-EphA4 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-EphA4 antibody as an active ingredient for damaging EphA4-expressing cells using antibody effector function. Since EphA4 is strongly expressed in pancreatic cancer cells, the present invention is particularly useful in pancreatic cancer therapies.

Abstract: An absorbent article has a liquid permeable top sheet (5) making contact with the wearer's skin surface, a liquid impermeable back sheet (6) making contact with the surface of underwear, and an absorber (7) mounted between the top sheet (5) and the back sheet (6) and capable of absorbing a bodily liquid. The an absorber (7) has a projected portion (2) which is a portion formed on a lower layer absorber (8) by overlaying an upper layer absorber (9) on the lower layer absorber (8), and the upper layer absorber (9) has smaller dimensions in the longitudinal and lateral directions than the lower layer absorber (8). A first recessed portion (3) is provided around the projected portion (2) so as to surround the projected portion (2). The first recessed portion (3) is formed by a continued portion (3a) and an intermittent portion (4).

Abstract: The present invention is based on the discovery that the cytoxicity of anti-desmocollin 2 (DSC2) antibodies can be used for treating various cancers including lung, colon, pancreatic, prostate, breast, gastric or liver cancers. Specifically, the present invention provides antibodies against DSC2 that have effector function. Furthermore, the present invention provides methods and pharmaceutical compositions that comprise anti-DSC2 antibody as an active ingredient for damaging DSC2-expressing cells via the effector function of the antibody.

Abstract: The present invention relates to the use of cytoxicity based on the effector function of anti-EphA4 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-EphA4 antibody as an active ingredient for damaging EphA4-expressing cells using antibody effector function. Since EphA4 is strongly expressed in pancreatic cancer cells, the present invention is particularly useful in pancreatic cancer therapies.

Abstract: The present invention relates to the use of cytotoxicity based on the effector function of anti-CDH3 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient for damaging CDH3-expressing cells using antibody effector function. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.

Abstract: The present invention relates to the use of cytoxicity based on the effector function of anti-GFRA1 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-GFRA1 antibody as an active ingredient for damaging GFRA1-expressing cells using antibody effector function. Since GFRA1 is strongly expressed in breast, gastric, liver, renal or lung cancer cells, the present invention is useful in breast, gastric, liver, renal or lung cancer therapies.

Abstract: The present invention is based on the discovery that the cytoxicity of anti-desmocollin 2 (DSC2) antibodies can be used for treating various cancers including lung, colon, pancreatic, prostate, breast, gastric or liver cancers. Specifically, the present invention provides antibodies against DSC2 that have effector function. Furthermore, the present invention provides methods and pharmaceutical compositions that comprise anti-DSC2 antibody as an active ingredient for damaging DSC2-expressing cells via the effector function of the antibody.

Abstract: This invention relates to the structure of multiple registers used in image signal processing, and aims to simplify the register structure and to reduce the power consumption of the registers and the time required for testing an image signal processing LSI with the registers. A semiconductor integrated circuit according to the invention has a clock generation circuit and a clock buffer circuit for generating a plurality of clock signals, a register group including a plurality of registers connected in series and operable in synchronism with the clock signals, at least one combinational circuit connected to the register group, and means for selecting one of a normal operation mode and a scan test mode for the register group. The clock generation circuit receives a system clock CP.sub.IN, a scan test mode selection signal S.sub.MODEN, and clock CPS.sub.IN, and outputs a clock .phi. and a clock (.phi..sub.1 bar) controlled by the signal S.sub.